logo

Vascular Biogenics Ltd. (VBLT)



Trade VBLT now with
  Date
  Headline
12/27/2017 7:05:53 AM VBL Therapeutics Announces First Patient In Phase 3 Trial Of VB-111 In Platinum Resistant Ovarian Cancer
11/17/2017 9:05:52 AM VBL Therapeutics Prices Prior Announced Underwritten Public Offering Of 2.5 Mln Shares For Gross Proceeds Of $18.75 Mln
11/14/2017 7:10:56 AM VBL Therapeutics Q3 Comprehensive Loss $6.5 Mln Or $0.24 Per Share
11/6/2017 7:22:50 AM VBL Therapeutics And NanoCarrier Sign Exclusive Agreement For VB-111 In Japan
10/20/2017 7:04:42 AM VBL Therapeutics Announces Orphan Drug Designation For VB-111 In Europe
10/2/2017 7:13:21 AM VBL Unveils Positive Outcome In Third, Final DSMC Review Of Phase 3 GLOBE Trial Investigating VB-111 In Recurrent GBM
8/14/2017 7:09:26 AM VBL Therapeutics Q2 Net Loss $4.9 Mln Or $0.18 Per Share
6/15/2017 7:07:24 AM VBL Therapeutics Names Corinne Epperly As U.S. COO
5/15/2017 7:17:17 AM VBL Therapeutics Q1 Net Loss $5.0 Mln Or $0.19/shr Vs. Net Loss $4.7 Mln Or $0.21/shr Last Year